A Multisite Study of Long-term Remission and Relapse of Type 2 Diabetes Mellitus Following Gastric Bypass
- 5.5k Downloads
Gastric bypass has profound effects on glycemic control in adults with type 2 diabetes mellitus. The goal of this study was to examine the long-term rates and clinical predictors of diabetes remission and relapse among patients undergoing gastric bypass.
We conducted a retrospective cohort study of adults with uncontrolled or medication-controlled type 2 diabetes who underwent gastric bypass from 1995 to 2008 in three integrated health care delivery systems in the USA. Remission and relapse events were defined by diabetes medication use and clinical laboratory measures of glycemic control. We identified 4,434 adults with uncontrolled or medication-controlled type 2 diabetes who had gastric bypass.
Overall, 68.2 % (95 % confidence interval [CI], 66 and 70 %) experienced an initial complete diabetes remission within 5 years after surgery. Among these, 35.1 % (95 % CI, 32 and 38 %) redeveloped diabetes within 5 years. The median duration of remission was 8.3 years. Significant predictors of complete remission and relapse were poor preoperative glycemic control, insulin use, and longer diabetes duration. Weight trajectories after surgery were significantly different for never remitters, relapsers, and durable remitters (p = 0.03).
Gastric bypass surgery is associated with durable remission of type 2 diabetes in many but not all severely obese diabetic adults, and about one third experience a relapse within 5 years of initial remission. More research is needed to understand the mechanisms of diabetes relapse, the optimal timing of surgery in effecting a durable remission, and the relationship between remission duration and incident microvascular and macrovascular events.
KeywordsGastric bypass Diabetes Remission Relapse
The team would like to gratefully acknowledge the contributions of our project managers Rene Hawkes (Group Health Research Institute), Cathy Chou (Kaiser Permanente Northern California), and Mark Pierce (Kaiser Permanente Northern California) and programmers Mary Becker (HealthPartners), Mike Sorel (Kaiser Permanente Northern California), and Julie Liu (Kaiser Permanente Southern California). We would also like to acknowledge the scientific and clinical input of our Technical Expert Panel members: Edward H. Livingston, MD, FACS (University of Texas Southwestern); David R. Flum, MD, MPH, FACS (University of Washington); and Melinda Maggard Gibbons, MD (University of California at Los Angeles).
This research was conducted by Group Health Research Institute, HealthPartners, Kaiser Permanente Northern California, Kaiser Permanente Southern California, and the University of Wisconsin. This project was funded under contract no. HHSA290-2005-0033-I-TO10-WA1 from the Agency for Healthcare Research and Quality, US Department of Health and Human Services as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program.
Conflicts of Interest
- 6.Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012 (in press).Google Scholar
- 7.Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012 (in press).Google Scholar
- 15.Phurrough S, Salive ME, Brechner RJ, Meltzer A. Coverage decision memorandum for surgery for diabetes. 2008. Services CfMaM, ed.Google Scholar
- 23.Collett D. Modeling survival data in medical research. 2003; Chapman and Hall/CRC.Google Scholar
- 24.Hastie TJ. Generalized additive models. In: Chambers JM, Hastie TJ, editors. Statistical models in S. Yonkers: T Bell Laboratories; 1992. p. 249–308.Google Scholar
- 25.Diggle P, Heagerty P, Liang K, Zeger SL. Analysis of longitudinal data. 2nd ed. Oxford: Oxford University Press; 2002.Google Scholar
- 29.Arterburn D, Schauer DP, Wise RE, et al. Change in predicted 10-year cardiovascular risk following laparoscopic Roux-en-Y gastric bypass surgery. Obes Surg 2008.Google Scholar
- 32.Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research G. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–67.CrossRefGoogle Scholar
- 33.Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. Am J Ophthalmol 2000; 129:704–5.Google Scholar
- 34.Cleary PA, Orchard TJ, Genuth S, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2006;55:3556–65.PubMedCrossRefGoogle Scholar